Literature DB >> 3815354

Immunological detection of DNA damage caused by melphalan using monoclonal antibodies.

M J Tilby, J M Styles, C J Dean.   

Abstract

Immunological detection of melphalan adducts on DNA should permit new types of clinical and experimental investigations. Five cloned rat hybridoma cell lines were derived, each producing an antibody that bound to DNA alkylated with melphalan (phenylalanine mustard) but not to normal DNA. Further characterization of one melphalan specific antibody (MP5/73) used a competitive fluorogenic enzyme-linked immunoabsorbent assay. Using denatured DNA, 50% inhibition of antibody binding was caused by 30 fmol of total melphalan adducts (determined using radioactive melphalan) per assay well. Denatured control DNA caused 16 to 24% inhibition at 45 micrograms (130 nmol)/well, the maximum concentration tested. Adducts on RNA behaved similarly to those on denatured DNA. Adducts on native DNA caused 50% inhibition at 272 to 1335 fmol/well dependent upon alkylation frequency and sonication treatment. Native control DNA caused no detectable inhibition at 45 micrograms/well. The adducts recognized by the antibody were thermo- and alkali labile. Denaturation of the alkylated DNA by moderate heating in the presence of 75% formamide gave 50% inhibition at 50 fmol/well, indicating that only 5% of the recognized adducts could bind antibody in native DNA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815354

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  PCR-based methods for detecting DNA damage and its repair at the sub-gene and single nucleotide levels in cells.

Authors:  Keith A Grimaldi; Claire J McGurk; Peter J McHugh; John A Hartley
Journal:  Mol Biotechnol       Date:  2002-02       Impact factor: 2.695

2.  Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma.

Authors:  Ryan S Turley; Andrew N Fontanella; James C Padussis; Hiroaki Toshimitsu; Yoshihiro Tokuhisa; Eugenia H Cho; Gabi Hanna; Georgia M Beasley; Christina K Augustine; Mark W Dewhirst; Douglas S Tyler
Journal:  Clin Cancer Res       Date:  2012-04-10       Impact factor: 12.531

3.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

4.  Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.

Authors:  Inusha U De Silva; Peter J McHugh; Peter H Clingen; John A Hartley
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

5.  Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.

Authors:  P M Terheggen; B G Floot; E L Lempers; O van Tellingen; A C Begg; L den Engelse
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.

Authors:  Ryan S Turley; Yoshihiro Tokuhisa; Hiroaki Toshimitsu; Michael E Lidsky; James C Padussis; Andrew Fontanella; Wanleng Deng; Christina K Augustine; Georgia M Beasley; Michael A Davies; Mark W Dewhirst; Douglas S Tyler
Journal:  Ann Surg       Date:  2015-02       Impact factor: 12.969

7.  Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Authors:  B Peng; M J Tilby; M W English; L Price; A D Pearson; A V Boddy; D R Newell
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.